- Details
- Rashid Sayyid and Zach Klaassen discuss the ARANOTE trial, a phase III study evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. They highlight the trial's design, which randomized 669 patients to darolutamide plus ADT or placebo plus ADT. The study meets its primary endpoint, showing significant improvement in radiographic progression-free survival for the darolutami...
|
- Details
- Christos Kyriakopoulos discusses the phase 1/2 trial of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer. Dr. Kyriakopoulos discusses the trial design, focusing on the completed phase 1 results and ongoing phase 2 study. The phase 1 data show the combination is well-tolerated with promising efficacy, including an 88% PSA-90 response rate in evaluable patients. The t...
|
- Details
- Fred Saad and Neal Shore discuss the ARANOTE trial with Zach Klaassen, exploring the use of darolutamide plus ADT in metastatic hormone-sensitive prostate cancer. They highlight the trial's diverse patient population and impressive results, including a 46% reduction in radiographic progression-free survival risk. The conversation covers the efficacy of this doublet therapy in various subgroups, pa...
|
- Details
- Neeraj Agarwal interviews Niven Mehra about the INSPIRE trial. The study examines the efficacy of nivolumab and ipilimumab combination therapy in molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC). Dr. Mehra discusses the trial's design, which focuses on four subgroups: mismatch repair deficiency, high tumor mutational burden, CDK12 inactivation, and BRCA2 m...
|
- Details
- Oliver Sartor interviews William Kevin Kelly about findings on AMG 509 (Xaluritamig), a STEAP1-targeted T-cell engager for advanced prostate cancer. Dr. Kelly discusses the drug's mechanism, dosing optimization, and efficacy in heavily pretreated patients. He highlights the manageable cytokine release syndrome and the need to address musculoskeletal side effects. The conversation covers impressive...
|
- Details
- Himisha Beltran discuses DLL3, a promising target for neuroendocrine prostate cancer treatment. Dr. Beltran explains that DLL3 is highly expressed in neuroendocrine and small cell prostate cancers, making it an attractive therapeutic target. She reviews recent clinical trials of DLL3-targeted T-cell engagers, including Tarlatamab and MK-6070, highlighting their potential efficacy in treating neuro...
|
- Details
- Oliver Sartor hosts Jake Berchuck to discuss a novel epigenomic liquid biopsy platform for determining PSMA expression in prostate cancer. Dr. Berchuck explains how the assay analyzes cell-free DNA to infer tumor PSMA expression, showing strong correlation with PSMA PET scan results. They explore the potential of this technology to provide real-time, non-invasive monitoring of tumor drug target ex...
|
- Details
- Oliver Sartor and Ken Herrmann discuss the current state and future directions of PSMA ligand therapy in prostate cancer treatment. Dr. Herrmann presents recent findings from various clinical trials, including PSMAfore and ENZA-p, which explore the use of lutetium-PSMA therapy in different stages of prostate cancer. They examine the potential of combining lutetium-PSMA with other treatments like e...
|
- Details
- Nicholas James and Gerhardt Attard discuss findings from the STAMPEDE trial, focusing on molecular profiling of prostate cancer tumors. They explore the use of the Decipher® genomic classifier as a prognostic and predictive tool for treatment decisions in metastatic prostate cancer. The conversation covers the test's ability to identify patients who are likely to benefit from abiraterone and, more...
|
- Details
- Oliver Sartor host Dana Rathkopf for a discussion on BMS-986365, a novel androgen receptor ligand-directed degrader for prostate cancer treatment. Dr. Rathkopf discusses the drug's unique dual mechanism of action, which both degrades and competitively inhibits the androgen receptor. She presents data from the phase I/II trial, highlighting the drug's efficacy, particularly in patients without prio...
|
